News

CEO Message on xFOREST's 5th Anniversary

When we founded xFOREST Therapeutics, our vision of it in 5 years felt like a dream in the mist. I still vividly remember those early days, filled with excitement and uncertainty, when we kept running toward an unknown future.

Thanks to our wonderful team, our trusted VC investors, pharmaceutical partners, advisors, venture incubation organizers, and all those who believed in and supported our mission, we are fortunate and proud to welcome the start of our 6th year.

To all of you, I extend my sincere gratitude. Thank you.

From the beginning, xFOREST has remained committed to one ambitious goal – bringing RNA-targeted small molecule drugs to patients, based on our own technology.

The road has been far from easy, but we have never doubted the unique strengths of our proprietary RNA structure library technology and its global applicability. Step by step, and through continuous innovation, we’ve made strong progress.

In the broader timeline of drug development, five years may seem short. But within this time, we have grown our team with outstanding researchers, launched joint development projects with multiple pharmaceutical companies, and built a solid track record.

Now, xFOREST stands at an inflection point. 

In addition to our drug discovery support business, last year we launched a lead compound generation platform with a total budget of $10.5 million. We’re also launching a new series of innovative technologies in RNA-targeted drug discovery – from new splicing-targeting HTS to 3D structure prediction platforms.

Over the next five years, we aim to strengthen our role as a central hub for RNA-targeted drug discovery in Japan, while actively advancing toward recognition as a global leader in RNA-targeted therapeutics.

We hope you will continue supporting xFOREST as we embrace this next chapter with the same boldness that first inspired our journey.

Shunichi KASHIDA

xFOREST Therapeutics Co., Ltd.
Representative Director, President, and CEO